VK2735
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
VK2735 is a dual GLP-1/GIP receptor agonist for rapid weight loss, marketed as an alternative to GLP-1-only drugs. Early human trials show up to 14.7% weight loss in 13 weeks and high responder rates, but the evidence base is still thin and long-term safety data are lacking. The main risk is gastrointestinal side effects, plus a theoretical thyroid tumor concern. It is not FDA-approved and circulates as unregulated research-grade product.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
VK2735 is a dual GLP-1/GIP receptor agonist developed by Viking Therapeutics for the treatment of obesity and related metabolic disorders. It belongs to the same pharmacological class as tirzepatide (Mounjaro/Zepbound) and is being developed in both subcutaneous (weekly injection) and oral (daily tablet) formulations. VK2735 works by simultaneously activating two incretin hormone receptors — GLP-1 and GIP — which together reduce appetite, improve insulin sensitivity, slow gastric emptying, and promote weight loss.
In the Phase 2 VENTURE trial, subcutaneous VK2735 delivered up to 14.7% body weight loss in 13 weeks, with no plateau observed, and up to 88% of participants achieving at least 10% weight loss. Most adverse events were mild or moderate gastrointestinal symptoms. Participants maintained over 80% of their weight loss seven weeks after treatment ended.
Viking is conducting the VANQUISH Phase 3 registrational program, which includes two large trials (VANQUISH-1 with approximately 4,650 patients and VANQUISH-2 with approximately 1,100 patients with type 2 diabetes) evaluating weekly subcutaneous VK2735 over 78 weeks; both have completed enrollment. An oral formulation showed dose-dependent weight loss of up to 5.3% in 28 days in a Phase 1 study, and a 13-week Phase 2 oral trial began in January 2025. If Phase 3 results are positive, VK2735 could become a major competitor to tirzepatide in the GLP-1/GIP obesity market.
How it works in the body
A dual agonist that activates both GLP-1 and GIP receptors simultaneously. GLP-1 receptor activation slows gastric emptying, reduces appetite, and improves insulin sensitivity. GIP co-activation enhances the metabolic effects and may improve tolerability compared to GLP-1 alone, producing greater weight loss through complementary incretin pathways.
Research overview
VK2735 was selected from a series of internally developed dual GLP-1/GIP receptor agonists by Viking Therapeutics. Preclinical data presented at ObesityWeek 2021 demonstrated improvements in the metabolic profile of diet-induced obese mice. A Phase 1 SAD/MAD trial initiated in 2022 showed VK2735 was safe and well-tolerated when dosed subcutaneously for up to 28 days, with mean weight loss of up to 18 pounds. The pivotal Phase 2 VENTURE trial (NCT06068946, n=176) achieved its primary and all secondary endpoints, with weight loss up to 14.7% from baseline after 13 weekly doses. Pharmacokinetic data showed a half-life of 170-250 hours, and weight loss was maintained after treatment ended. The oral formulation Phase 1 MAD study showed dose-dependent weight loss up to 5.3% in 28 days, with all adverse events mild or moderate. A Phase 2 oral trial was initiated in January 2025. The Phase 3 VANQUISH program includes VANQUISH-1 (NCT07104500, n~4,650 adults with obesity) and VANQUISH-2 (n~1,100 adults with T2D and obesity), both evaluating weekly subcutaneous doses of 7.5 mg, 12.5 mg, and 17.5 mg over 78 weeks. VANQUISH-1 completed enrollment ahead of schedule, and both VANQUISH trials have now completed enrollment; their results remain pending. An exploratory maintenance study (n~180) is also underway. The VENTURE results were published in the peer-reviewed journal Obesity in January 2026.
Who researches VK2735?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People researching GI and digestive health
Studied for gastrointestinal protection, gut lining repair, or digestive support.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(4)
Rated by level of concern
Gastrointestinal adverse events (nausea, vomiting, GI disturbances)
HighPMID 41508550; ClinicalTrials.gov NCT06068946
Dehydration (from GI side effects)
ModerateFDA labeling for GLP-1/GIP receptor agonists (Zepbound/tirzepatide, Wegovy/semaglutide); PMID 41508550
Limited long-term safety data
HighClinicalTrials.gov NCT06068946, NCT06828055, NCT07104500, NCT07104383
Thyroid C-cell tumor risk (GLP-1 class warning)
TheoreticalFDA boxed warnings for liraglutide, semaglutide, tirzepatide (class); no VK2735-specific data published
Interaction summary(8)
Rated by direction with this peptide
Insulin and insulin secretagogues (sulfonylureas, glinides)
CautionModerateAdding an incretin agonist to insulin or a sulfonylurea raises hypoglycemia risk and generally requires dose reduction of the background agent — an established label-level interaction for the approved GLP-1/GIP class that applies mechanistically to VK2735, now confirmed in Phase 3 in type 2 diabetes (VANQUISH-2, NCT07104383).
FDA labeling for tirzepatide/semaglutide (Drug Interactions); ClinicalTrials.gov NCT07104383
Other GLP-1 or GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide)
CautionHighConcurrent use is duplicative pharmacology with additive GI toxicity and no added benefit; VK2735 trials excluded recent GLP-1 users, and there is no supporting evidence for using two incretin agonists together. High severity is used here as a do-not-combine flag rather than a quantified VK2735-specific finding.
ClinicalTrials.gov NCT06828055 / NCT06068946 exclusion criteria
Oral drugs with narrow therapeutic index or absorption sensitive to gastric emptying (levothyroxine, warfarin, digoxin)
CautionModerateDelayed gastric emptying can alter the rate and, for some agents, the extent of oral absorption, so INR, thyroid function, or drug levels should be monitored more closely during initiation and titration — a documented class effect, not a VK2735-specific study finding.
FDA labeling for GLP-1 receptor agonists (delayed gastric emptying / drug interaction sections)
Oral hormonal contraceptives
CautionModerateThe tirzepatide label advises a non-oral or barrier contraceptive method for 4 weeks after initiation and after each dose escalation due to reduced oral contraceptive exposure. This precaution is specific to the GIP-containing agent (not carried by pure GLP-1 semaglutide), so the analogy to the GIP/GLP-1 dual agonist VK2735 is reasonable, though no VK2735 interaction study has been published.
FDA labeling for tirzepatide (Mounjaro/Zepbound), Drug Interactions
Diuretics, ACE inhibitors, ARBs, SGLT2 inhibitors, NSAIDs (volume-depletion/renal risk)
CautionModerateGI-driven volume depletion combined with these agents is the recognized pathway to acute kidney injury reported with incretin agonists; the risk is additive rather than drug-specific and is an extrapolated class effect, not a VK2735 trial finding.
FDA labeling for GLP-1 receptor agonists (Acute Kidney Injury warnings)
General anesthesia and procedural sedation
CautionModerateDelayed gastric emptying can leave residual gastric contents despite standard fasting; anesthesiology guidance recommends holding weekly GLP-1 agonists (typically ~1 week) or treating the patient as full-stomach. Extends to VK2735 by mechanism, not by direct study.
American Society of Anesthesiologists guidance on GLP-1 receptor agonists and perioperative fasting (2023/2024)
Alcohol
CautionLowCompounds nausea, vomiting, and dehydration and adds hypoglycemia risk when combined with insulin or sulfonylureas; a practical rather than a demonstrated pharmacokinetic interaction. Low severity appropriately reflects this.
Mechanistic / GLP-1 class clinical guidance; no VK2735-specific data
Drugs independently associated with pancreatitis or a history of pancreatitis
CautionTheoreticalPancreatitis is a labeled class concern for incretin agonists and VK2735 trials excluded relevant pancreatic history, but no causal VK2735 signal has been reported and additive risk with other pancreatitis-associated agents remains hypothetical. Correctly tiered Theoretical.
FDA labeling for GLP-1/GIP receptor agonists (Pancreatitis warnings); ClinicalTrials.gov NCT06068946 exclusion criteria
Known risks(4)
Gastrointestinal adverse events (nausea, vomiting, GI disturbances)
Mild to ModerateNausea was the most common AE (43% of VK2735 patients vs 20% placebo), with 68% of nausea reports classified as mild. Vomiting occurred in 18% of treated patients. GI events decreased in frequency after initial dosing.
Dehydration (from GI side effects)
Moderate / RareOne participant experienced serious dehydration judged probably related to study drug and atrial fibrillation judged possibly related; treatment was stopped. Patients should maintain adequate hydration, especially during dose escalation.
Limited long-term safety data
Peer-reviewed VENTURE results cover 13 weeks of treatment. Viking also reported results through 33 weeks from a maintenance study on September 22, 2026. The 78-week Phase 3 trials remain ongoing; cardiovascular outcomes and other long-term effects are not yet known.
Thyroid C-cell tumor risk (GLP-1 class warning)
Theoretical / PrecautionarySome approved GLP-1–based drugs carry a precaution based on thyroid C-cell tumors observed in rodent studies. This has not been confirmed in humans.
Drug interactions(4)
Insulin and insulin secretagogues (sulfonylureas, meglitinides)
Co-administration may increase risk of hypoglycemia due to VK2735's incretin-mediated enhancement of insulin secretion. Dose adjustments of concomitant diabetes medications may be required.
Other GLP-1 or GLP-1/GIP receptor agonists
Co-administration not recommended due to overlapping mechanisms. Additive GI side effects and risk of excessive appetite suppression.
Oral medications with narrow therapeutic index (warfarin, levothyroxine)
GLP-1/GIP agonists slow gastric emptying, which may alter absorption of co-administered oral drugs. Monitor closely during dose escalation.
Oral contraceptives
Delayed gastric emptying may reduce absorption of oral contraceptives. Backup contraception advised during dose escalation periods.
Research & benefits
Evidence base
- Evidence Level
- Moderate-Strong Evidence
- Total Studies
- 8
- Human Participants
- 6100
VK2735 has completed Phase 1 and Phase 2 trials and is now in Phase 3. The Phase 2 VENTURE trial (n=176) was a randomized, double-blind, placebo-controlled study that met all primary and secondary endpoints with up to 14.7% weight loss in 13 weeks. Results from VENTURE have been published in the journal Obesity. Both Phase 3 VANQUISH trials have completed enrollment; their efficacy and safety results remain pending.
Researched for(5)
Rated by confidence in the evidence
Rapid and substantial weight loss (up to 14.7% in 13 weeks with no plateau)
HighHuman randomized trial showed up to 14.7% weight loss at 13 weeks, no plateau.
PMID 41508550 (Obesity (Silver Spring) 2026;34(3):537-549; Bays et al.); ClinicalTrials.gov NCT06068946
High responder rate — up to 88% of patients achieved 10% or greater weight loss
MediumPhase 2 VENTURE trial: 88% of patients lost 10%+ weight versus 4% on placebo.
PMID 41508550 (Bays et al., Obesity, 2026 — VENTURE trial); ClinicalTrials.gov NCT06068946
Durable weight loss maintenance (over 80% of weight loss maintained 7 weeks post-dosing)
MediumSmall follow-up subset of trial participants retained most weight loss 7 weeks post-dosing.
PMID 41508550 (follow-up subset); ClinicalTrials.gov NCT06068946
Oral formulation shows dose-dependent weight loss (up to 5.3% in 28 days)
MediumSmall 28-day Phase 1 dose-escalation cohort; figure unconfirmed in any peer-reviewed publication.
ClinicalTrials.gov NCT05203237 (Part C, oral MAD); NCT06828055 (Phase 2 oral, confirmed)
Favorable safety profile with low discontinuation rates comparable to placebo
MediumShort-term injectable trial data show good tolerability; long-term and oral safety unconfirmed.
PMID 41508550; ClinicalTrials.gov NCT06068946, NCT06828055
Benefits(5)
Rapid and substantial weight loss (up to 14.7% in 13 weeks with no plateau)
Phase 2 VENTURE trial (n=176, published in Obesity 2026)
High responder rate — up to 88% of patients achieved 10% or greater weight loss
Phase 2 VENTURE trial (Viking press release Feb 2024)
Durable weight loss maintenance (over 80% of weight loss maintained 7 weeks post-dosing)
Phase 2 VENTURE PK subset (ObesityWeek 2024 poster)
Oral formulation shows dose-dependent weight loss (up to 5.3% in 28 days)
Phase 1 MAD oral study (Viking press release Mar 2024, ObesityWeek 2024)
Favorable safety profile with low discontinuation rates comparable to placebo
Phase 2 VENTURE trial — 13% discontinuation across VK2735 arms vs 14% placebo
Key studies(4)
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study
Phase 2 RCTn=17613 weeksViking Therapeutics investigators
Obesity (journal of The Obesity Society)
2026
VK2735 achieved statistically significant weight loss up to 14.7% from baseline (13.1% placebo-adjusted) after 13 weekly subcutaneous doses. Up to 88% of patients achieved >=10% weight loss vs 4% placebo. No plateau was observed. Safety was encouraging with 92% of AEs mild or moderate.
Phase 1 SAD/MAD Study of Subcutaneous VK2735 in Healthy Obese Volunteers
Phase 1 SAD/MADn=48 (estimated)28 daysViking Therapeutics investigators
Company data (presented ObesityWeek 2024)
2023
VK2735 was safe and well-tolerated with mean weight loss up to 18 lbs from baseline. Half-life of 170-250 hours supports weekly dosing. Predictable pharmacokinetic profile with Tmax of 75-90 hours.
Phase 1 MAD Study of Oral VK2735 in Adults with Obesity
Phase 1 MADInitial March 2024 report: 47 participants in the safety population, including 37 receiving VK2735 and 10 receiving placebo; higher-dose cohorts were reported separately.28 daysViking Therapeutics investigators
Company data (presented ObesityWeek 2024)
2024
Oral VK2735 showed dose-dependent weight loss up to 5.3% from baseline (3.3% placebo-adjusted) at 28 days; the maximum placebo-adjusted reduction was 3.6% at the day-34 follow-up. Up to 57% of treated subjects achieved >=5% weight loss vs 0% placebo. All AEs mild or moderate.
VANQUISH-1: Phase 3 Study of VK2735 for Weight Management
Phase 3 RCT (ongoing)n=4,650 (enrolled)78 weeksViking Therapeutics (ongoing)
ClinicalTrials.gov
2025
Ongoing Phase 3 registrational trial evaluating subcutaneous VK2735 (7.5 mg, 12.5 mg, 17.5 mg weekly) vs placebo in adults with obesity or overweight with comorbidities. Over-enrolled ahead of schedule.
Regulation & availability
Why researchers look at it
VK2735 delivered some of the most impressive early-phase weight loss data seen in the GLP-1/GIP class — up to 14.7% in just 13 weeks with no plateau. With both injectable and oral formulations in development and a massive Phase 3 program underway, it represents one of the most promising next-generation obesity treatments in the pipeline.
- Estimated cost
- Not yet available — Phase 3 trials ongoing (Viking Therapeutics)
- FDA status
- VK2735 is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. The VANQUISH Phase 3 registrational program is ongoing, with VANQUISH-1 (obesity) fully enrolled and VANQUISH-2 (obesity with T2D) fully enrolled, as announced on March 26, 2026.
- WADA status
- Prohibited at all times under WADA S0 because VK2735 remains an unapproved investigational drug, even though it is not named individually. The 2026 Monitoring Program covers markers of semaglutide and tirzepatide; this does not exempt VK2735. Athletes should consult their anti-doping authority.
- Prescribability
- No — Investigational (Phase 3 ongoing)
- Availability
- VK2735 remains investigational and is not available as an approved prescription treatment as of October 14, 2026. The injectable VANQUISH Phase 3 trials are fully enrolled, with completion expected in 2027. Viking announced initiation of the oral SUNRISE Phase 3 program on October 14, 2026. Access depends on eligibility for an enrolling clinical trial. Approval timing remains uncertain.
International status
US
Phase 3 clinical trials (Viking Therapeutics)
Worldwide
Investigational — not yet approved anywhere
Regulatory timeline(14)
- 2021-11Preclinical data on VK2735 presented at ObesityWeek 2021
- 2022Phase 1 SAD/MAD subcutaneous trial initiated
- 2023-Q1Phase 1 subcutaneous results announced — safe, up to 18 lbs weight loss in 28 days
- 2023-Q1Phase 1 MAD oral formulation study initiated
- 2023-09Phase 2 VENTURE trial initiated (NCT06068946), enrollment expanded to 176 from 125
- 2024-02VENTURE Phase 2 topline results — up to 14.7% weight loss in 13 weeks, all endpoints met
- 2024-03Phase 1 oral VK2735 positive results — dose-dependent weight loss up to 5.3% in 28 days
- 2024-11ObesityWeek 2024 — VENTURE PK data showing weight loss maintained after treatment; additional oral cohort data
- 2025-01Phase 2 oral VK2735 trial initiated (13 weeks, obesity)
- 2025-H1Phase 3 VANQUISH-1 and VANQUISH-2 trials initiated
- 2025-H2VANQUISH-1 enrollment completed (~4,650 patients) ahead of schedule
- 2026-01VENTURE Phase 2 results published in journal Obesity
- 2026-Q1VANQUISH-2 enrollment completed; maintenance study enrolled (~180 patients)
- 2027 (expected)Phase 3 VANQUISH results readout anticipated
Sources & FAQs
Research sources(4)
Frequently asked questions(4)
How does VK2735 compare to tirzepatide (Zepbound/Mounjaro)?
VK2735 and tirzepatide are both dual GLP-1/GIP receptor agonists. In the Phase 2 VENTURE trial, VK2735 achieved up to 14.7% weight loss in just 13 weeks — a rate that, if sustained, could be competitive with or exceed tirzepatide's results. However, head-to-head Phase 3 data are not yet available, so direct comparison is premature.
Will VK2735 come in a pill form?
Yes, Viking is developing both a subcutaneous injection (weekly) and an oral tablet (daily). The oral formulation showed promising early results in Phase 1, with up to 5.3% weight loss in 28 days. A Phase 2 oral trial began in January 2025.
When might VK2735 be available to patients?
The Phase 3 VANQUISH program is expected to read out results in 2027. If successful, an NDA filing would follow, with potential FDA approval in 2028 at the earliest. Timeline could shift depending on trial results and regulatory interactions.
What are the main side effects of VK2735?
In the Phase 2 VENTURE trial, the most common side effects were gastrointestinal: nausea (43% vs 20% placebo), vomiting (18%), and other GI symptoms. The vast majority (92%) were mild or moderate. Discontinuation rates were low and comparable to placebo.